Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31171921 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL6033481 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL1459603 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL6245300 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL6241582 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL31171990 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Carbon Monoxide SCHEMBL3038936 | 0.86 | TSHR (0.35) | TSHRTHRBLMNA | |
| SCHEMBL31009030 | 0.85 | FAAH (0.52) | LMNAMEN1KMT2AHSD17B10 | |
| SCHEMBL5865687 | 0.83 | — | — | |
| SCHEMBL29957532 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024234088-A1 | SYSTEMS AND METHODS FOR AI-BASED IONIZABLE LIPID DEVELOPMENT FOR LIPID NANOPARTICLE (LNP)-BASED CARGO MOLECULE DELIVERY | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2024-11-21 | — | — | WO | disclosed |
| CN-115429816-A | Cisplatin-bonded prodrug and preparation method and application thereof | 烟台大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-114621417-A | Optically active spiral polyfluorene block polyisonitrile copolymer and preparation method and application thereof | 合肥工业大学 | 2022-06-14 | — | — | CN | disclosed |
| US-7592351-B2 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20070099896-A1 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GRUENENTHAL GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099896-A1 | Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds | GIPR, CHUK, ITPA | TSHR 1545/4885THRB 3826/4885DNM1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.